For example, in patients with node-positive tumours of larger size (≥pT2) expressing both the oestrogen and progesterone receptor (26% of included patients), 6 versus 3 years of anastrozole resulted in an absolute improvement of 13.2% in the 10-year adapted disease-free survival (HR 0.64; 95% CI 0.47–0.88) (Supplementary Fig. S3B, Supplementary Table S2). This evidence concerns the gene PGR and neoplasm.